Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection. For those patients who remain non-resectable, a tailored treatment plan is proposed, consisting of arterial infusion chemotherapy in conjunction with radiotherapy, succeeded by a series of immune checkpoint inhibitors. The efficacy and safety of this integrated therapeutic strategy are meticulously assessed, with the goal of enhancing survival outcomes for patients with T4bNanyM0 HNSCC.

Trial Details

NCT ID
NCT06725498
Phase
PHASE2
Sponsor
Beijing Tongren Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Tislelizumab-jsgr
  • Cisplatin
  • Albumin-Bound Paclitaxel
  • Radiotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients with T4bNanyM0 Head and neck squamous cell carcinoma (hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer or oral cavity) with a…
  • Expected survival ≥3 months, with adequate organ function;
  • Investigators believe they can safely receive treatment with PD-1 combined with platinum and albumin-bound paclitaxel;
  • Age ≥18 years;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →